Clinical Trials Logo

Clinical Trial Summary

Non-commercial clinical study to assess: 1. efficacy of iCHRTL in patients with advanced squamous cell carcinoma of oral cavity, pharynx carcinoma, larynx carcinoma or paranasal sinus carcinoma. 2. tolerability of iCHRTL in patients with advanced squamous cell carcinoma of oral cavity, pharynx carcinoma, larynx carcinoma or paranasal sinus carcinoma. 3. molecular and biochemical effect of low doses of ionizing radiation.


Clinical Trial Description

40 patients with squamous cell carcinoma of oral cavity, pharynx, larynx or paranasal sinuses in stage III or IV, previously not treated for this reason and eligible for induction chemotherapy. Study treatment: Induction phase: Chemotherapy based on carboplatin 6 area under the curve (AUC) + paclitaxel 75 mg/m2 carboplatin 6 AUC 30-minute infusion on D: 1 (maximum carboplatin dose is 700 mg) paclitaxel 75 mg/m2 1-hour infusion on D: 1, 8, 15 Radiotherapy: D:1 - 2 x 0,5 Gy (first dose up to one hour after the end of the carboplatin infusion, second dose 3 to 6 hours later), D:2 - 2 x 0,5 Gy (interval between doses not less than 3 hours), D:8 and D:15 - 2 x 0,5 Gy (first dose up to one hour after the end of the chemotherapeutic infusion, second dose 3 to 6 hours later). 2 cycles of induction treatment are planned. Interval between the last day of cycle I and the first day of cycle II is 7 days. After 2 weeks from second cycle Positron emission tomography (PET) and Magnetic Resonance (MR), medical case conference and qualification to further treatment: Radiotherapy (RT), Chemo-radiotherapy (CHRT) or other, depending on the medical decision. Planned based on the optimal technique for a particular clinical case preferred: Intensity Modulated Radiation Therapy (IMRT). Preparation of IMRT plan will be based on computed tomography (CT) scans. Early tolerance of radiotherapy will be assessed for local reaction. At least once every 7 days. ;


Study Design


Related Conditions & MeSH terms


NCT number NCT05992610
Study type Interventional
Source Maria Sklodowska-Curie National Research Institute of Oncology
Contact Tomasz Rutkowski, MD PhD
Phone + 48 32 278 83 38
Email Tomasz.Rutkowski@io.gliwice.pl
Status Recruiting
Phase N/A
Start date February 17, 2022
Completion date March 31, 2026

See also
  Status Clinical Trial Phase
Completed NCT05217147 - An Investigation of Biomarker Candidate Molecules in Laryngeal Carcinoma
Recruiting NCT06287034 - The Role of the Free/Pedunculated Flap in Total Laryngectomy After (Chemo-)Radiotherapy Failure for Laryngeal Carcinoma: Impact on the Risk of Pharyngocutaneous Fistula (PCF)
Completed NCT00508664 - Docetaxel, Cisplatin (TP) + Radiation +/- Cetuximab in Larynx Carcinoma (CA) Phase 2
Recruiting NCT03942380 - Cell-free Tumor DNA in Head and Neck Cancer Patients N/A
Completed NCT00147732 - Randomized Trial of ARCON in Larynx Cancer Phase 3